Olga Shestova

9.3k total citations · 1 hit paper
71 papers, 4.0k citations indexed

About

Olga Shestova is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Olga Shestova has authored 71 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Oncology, 34 papers in Molecular Biology and 25 papers in Immunology. Recurrent topics in Olga Shestova's work include CAR-T cell therapy research (40 papers), Immune Cell Function and Interaction (14 papers) and Acute Myeloid Leukemia Research (8 papers). Olga Shestova is often cited by papers focused on CAR-T cell therapy research (40 papers), Immune Cell Function and Interaction (14 papers) and Acute Myeloid Leukemia Research (8 papers). Olga Shestova collaborates with scholars based in United States, Slovakia and France. Olga Shestova's co-authors include Warren S. Pear, Lanwei Xu, Saar Gill, Carl H. June, Marco Ruella, Ivan Maillard, Avinash Bhandoola, Martin Carroll, Jon C. Aster and Saad S. Kenderian and has published in prestigious journals such as Nature, Nucleic Acids Research and Journal of Clinical Investigation.

In The Last Decade

Olga Shestova

70 papers receiving 4.0k citations

Hit Papers

Single-cell analysis reveals fibroblast heterogeneity and... 2019 2026 2021 2023 2019 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Single-cell analysis reveals fibroblast heterogeneity and myeloid-derived adipocyte progenitors in murine skin wounds
    2019 358 citations Olga Shestova, Warren S. Pear et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Olga Shestova United States 27 1.9k 1.7k 1.5k 715 597 71 4.0k
Christoph Schaniel United States 26 2.7k 1.5× 876 0.5× 1.6k 1.1× 601 0.8× 299 0.5× 57 4.8k
Hanno Hock United States 25 2.1k 1.1× 1.0k 0.6× 1.5k 1.0× 1.0k 1.4× 740 1.2× 52 4.2k
Ken‐ichi Hanada United States 29 1.9k 1.0× 2.1k 1.3× 2.6k 1.8× 1.1k 1.5× 430 0.7× 56 4.9k
Olga I. Gan Canada 22 2.0k 1.1× 1.0k 0.6× 1.1k 0.8× 1.6k 2.2× 699 1.2× 51 4.1k
Johanna Olweus Norway 26 1.3k 0.7× 1.5k 0.9× 1.8k 1.2× 696 1.0× 253 0.4× 61 3.9k
Teri Johnson United States 9 1.8k 1.0× 859 0.5× 816 0.6× 1.5k 2.2× 441 0.7× 11 3.9k
Michael P. Rettig United States 27 977 0.5× 1.4k 0.8× 1.1k 0.8× 1.8k 2.5× 257 0.4× 122 3.5k
Robert A.J. Oostendorp Germany 35 1.6k 0.9× 664 0.4× 1.1k 0.7× 1.2k 1.7× 210 0.4× 109 3.8k
Carlos A. Ramos United States 35 2.1k 1.1× 4.3k 2.6× 2.0k 1.4× 721 1.0× 1.5k 2.4× 107 6.2k
Françoise Pflumio France 37 2.1k 1.1× 850 0.5× 1.4k 1.0× 1.6k 2.2× 824 1.4× 97 4.4k

Countries citing papers authored by Olga Shestova

Since Specialization
Citations

This map shows the geographic impact of Olga Shestova's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Olga Shestova with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Olga Shestova more than expected).

Fields of papers citing papers by Olga Shestova

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Olga Shestova. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Olga Shestova. The network helps show where Olga Shestova may publish in the future.

Co-authorship network of co-authors of Olga Shestova

This figure shows the co-authorship network connecting the top 25 collaborators of Olga Shestova. A scholar is included among the top collaborators of Olga Shestova based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Olga Shestova. Olga Shestova is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bhagwat, Anand, Maksim Shestov, Olga Shestova, & Saar Gill. (2024). CAR T Cells Accelerate Disease Progression in AMLs Harboring an Inflammatory Transcriptional Signature. Blood. 144(Supplement 1). 2040–2040. 1 indexed citations
2.
Veliz, Kimberly, Feng Shen, Olga Shestova, et al.. (2024). Deletion of CD38 enhances CD19 chimeric antigen receptor T cell function. SHILAP Revista de lepidopterología. 32(2). 200819–200819. 6 indexed citations
3.
4.
Diorio, Caroline, Kimberly Veliz, Olga Shestova, et al.. (2023). CD38 as a pan-hematologic target for chimeric antigen receptor T cells. Blood Advances. 7(16). 4418–4430. 33 indexed citations
5.
Gabbasov, Rashid, Alison Worth, Michael Ball, et al.. (2022). 371 Chimeric antigen receptor macrophages (CAR-M) sensitize solid tumors to anti-PD1 immunotherapy. Regular and Young Investigator Award Abstracts. A390–A390. 4 indexed citations
6.
Pierini, Stefano, Rashid Gabbasov, Linara Gabitova, et al.. (2021). Abstract 63: Chimeric antigen receptor macrophages (CAR-M) induce anti-tumor immunity and synergize with T cell checkpoint inhibitors in pre-clinical solid tumor models. Cancer Research. 81(13_Supplement). 63–63. 21 indexed citations
7.
Klichinsky, Michael, Marco Ruella, Olga Shestova, et al.. (2020). Abstract PR07: Human chimeric antigen receptor (CAR) macrophages for cancer immunotherapy. Cancer Immunology Research. 8(4_Supplement). PR07–PR07. 2 indexed citations
8.
Ruella, Marco, David M. Barrett, Olga Shestova, et al.. (2019). A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptor–positive cells. Blood. 135(7). 505–509. 24 indexed citations
9.
Ruella, Marco, Michael Klichinsky, Saad S. Kenderian, et al.. (2017). Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells. Cancer Discovery. 7(10). 1154–1167. 153 indexed citations
10.
11.
Klichinsky, Michael, Marco Ruella, Olga Shestova, et al.. (2017). Abstract 4575: Chimeric antigen receptor macrophages (CARMA) for adoptive cellular immunotherapy of solid tumors. Cancer Research. 77(13_Supplement). 4575–4575. 9 indexed citations
12.
Ruella, Marco, Saad S. Kenderian, Olga Shestova, et al.. (2016). The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma. Clinical Cancer Research. 22(11). 2684–2696. 141 indexed citations
13.
Kenderian, Saad S., Marco Ruella, Olga Shestova, et al.. (2016). Ruxolitinib Prevents Cytokine Release Syndrome after CART Cell Therapy without Impairing the Anti-Tumor Effect in a Xenograft Model. Blood. 128(22). 652–652. 31 indexed citations
14.
Ruella, Marco, Saad S. Kenderian, Olga Shestova, et al.. (2016). Kinase Inhibitor Ibrutinib Prevents Cytokine-Release Syndrome after Anti-CD19 Chimeric Antigen Receptor T Cells (CART) for B Cell Neoplasms. Blood. 128(22). 2159–2159. 8 indexed citations
15.
Chiang, Mark Y., Qīng Wáng, Sarah Stein, et al.. (2016). High selective pressure for Notch1 mutations that induce Myc in T-cell acute lymphoblastic leukemia. Blood. 128(18). 2229–2240. 24 indexed citations
16.
Gill, Saar, Sarah K. Tasian, Marco Ruella, et al.. (2014). Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor–modified T cells. Blood. 123(15). 2343–2354. 363 indexed citations
17.
Pajcini, Kostandin V., Teresa D’Altri, Lili Tu, et al.. (2014). The Notch1 transcriptional activation domain is required for development and reveals a novel role for Notch1 signaling in fetal hematopoietic stem cells. Genes & Development. 28(6). 576–593. 47 indexed citations
18.
Chiang, Mark Y., Lanwei Xu, Olga Shestova, et al.. (2008). Leukemia-associated NOTCH1 alleles are weak tumor initiators but accelerate K-ras–initiated leukemia. Journal of Clinical Investigation. 118(9). 3181–3194. 163 indexed citations
19.
Keeshan, Karen, Yiping He, Bas J. Wouters, et al.. (2006). Tribbles homolog 2 inactivates C/EBPα and causes acute myelogenous leukemia. Cancer Cell. 10(5). 401–411. 195 indexed citations
20.
Maillard, Ivan, Lili Tu, Arivazhagan Sambandam, et al.. (2006). The requirement for Notch signaling at the β-selection checkpoint in vivo is absolute and independent of the pre–T cell receptor. The Journal of Experimental Medicine. 203(10). 2239–2245. 162 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Christoph Schaniel Breakdown of academic impact, for papers by Hanno Hock Breakdown of academic impact, for papers by Ken‐ichi Hanada Breakdown of academic impact, for papers by Olga I. Gan Breakdown of academic impact, for papers by Johanna Olweus Breakdown of academic impact, for papers by Teri Johnson Breakdown of academic impact, for papers by Michael P. Rettig Breakdown of academic impact, for papers by Robert A.J. Oostendorp Breakdown of academic impact, for papers by Carlos A. Ramos Breakdown of academic impact, for papers by Françoise Pflumio
Rankless by CCL
2026